This episode of "This Week in Virology" features Dr. Daniel Griffin's clinical update, which begins with a strong condemnation of recent "attacks on science." These include proposals for saline placebo controls in new vaccine trials, a government initiative for a "next-generation" universal vaccine platform based on outdated 1940s technology (beta-propiolactone inactivated whole virus), and a Minnesota bill (HF3219) seeking to criminalize mRNA technology as "bioweapons." Dr. Griffin then reviews rising pertussis and measles cases in the US and globally, highlights the cardiovascular and dementia-risk-reduction benefits of the shingles vaccine, and discusses the influenza season which saw a high number of pediatric deaths. On a positive note, RSV cases are declining, with the Nirsevimab antibody showing significant success in protecting infants. For COVID-19, wastewater activity is low, and the updated KP.2 vaccine (BNT162b2) demonstrates good early effectiveness. The critical importance of early antiviral treatment for COVID-19 is re-emphasized, alongside concerns about the persistent over-prescription of antibiotics for viral respiratory infections. The update concludes with new research on Long COVID, indicating persistent symptoms in a significant portion of patients and revealing objective cardiovascular and pulmonary abnormalities detectable via advanced imaging.
0:00 Introduction & Context: The episode starts with introductions and a quotation from Margaret Thatcher regarding consensus, setting a tone for critical discussion.
3:24 "Attack on Science" Segment Begins: Dr. Griffin introduces a recurring section to address alarming trends and misinformation affecting science and public health.
3:36 Concerns over Saline Placebo Mandates for Vaccine Trials: Discussion of Robert F. Kennedy Jr.'s proposal to require saline placebo testing for new vaccines. This is critiqued as unethical and less scientifically informative than current standards, which often use adjuvant-only controls or existing vaccines to isolate the new antigen's effect.
10:52 Critique of HHS/NIH "Next-Generation" Universal Vaccine Platform: A new government initiative (Generation Gold Standard) plans to use beta-propiolactone inactivated whole virus technology from the 1940s (e.g., candidates BPL1357, BPL24910) for universal flu and coronavirus vaccines (including H5N1, SARS-CoV-2, SARS-CoV-1, MERS-CoV). This is heavily criticized as a regression from modern vaccine technology like mRNA.
15:20 Minnesota Bill (HF3219) Aims to Criminalize mRNA Technology: A proposed Minnesota bill seeks to designate mRNA injections and products as "bioweapons of mass destruction" and prohibit their use. This is condemned as baseless and a dangerous legislative overreach.
19:25 Alarming Rise in Pertussis (Whooping Cough) Cases: Pertussis cases in the US are nearly four times higher than the previous year, with approximately 6,600 documented. The severity, especially in infants, and its vaccine-preventability are emphasized.
20:39 Shingles Vaccine Linked to Reduced Cardiovascular Events and Dementia Risk: A large South Korean study found that the live zoster (shingles) vaccine was associated with a 23% reduction in overall cardiovascular events, adding to its known benefits against shingles and dementia.
22:19 Growing Measles Outbreaks in the US and Canada: Measles cases continue to surge, with over 935 confirmed in 30 US jurisdictions and over 1,177 in Canada, highlighting gaps in vaccination coverage.
23:13 Severe Flu Season with High Pediatric Mortality: While current influenza A activity is low, the past flu season resulted in 216 child deaths in the US, the highest in 15 years. Low childhood flu vaccination rates (less than half of children vaccinated) are a significant concern.
25:51 Positive RSV Update and Nirsevimab Efficacy: RSV season is waning. The monoclonal antibody Nirsevimab has shown remarkable success in protecting infants, with a Spanish study reporting a 63-78% reduction in RSV-related hospitalizations and a 75% drop in ICU admissions.
28:47 COVID-19: Updated KP.2 Vaccine Effectiveness: A US Veterans Affairs study on the BNT162b2 KP.2 vaccine demonstrated good early effectiveness: approximately 68% against COVID-19-associated hospitalizations and 56-57% against emergency/urgent care visits, though uptake remains low (3.7% in the study).
32:16 Critical Need for Early COVID-19 Antiviral Treatment: Research underscores that each day of delay in administering antiviral treatment (e.g., Paxlovid, Remdesivir) to at-risk COVID-19 patients increases the risk of hospitalization or death by 18%.
35:52 Persistent Over-Prescription of Antibiotics for Viral Infections: Despite awareness, unnecessary antibiotic prescribing continues, with about 35% of COVID-19 hospital admissions and 50% of other viral respiratory infection admissions still receiving antibiotics.
37:57 Long COVID: Symptom Persistence and Objective Pathological Findings:
An EU study reveals that one-third of COVID-19 patients experience long-lasting symptoms (fatigue, respiratory issues, brain fog) seven months post-infection.
Advanced imaging studies (PET/MRI, DECT) on Long COVID patients with persistent cardiopulmonary symptoms found objective abnormalities in 57%, including inflammation of heart muscle, pericardium, blood vessels, and myocardial scarring, 9-12 months after initial infection.
41:17 Call to Action: Support Science and Public Health: Listeners are encouraged to contact their government representatives to advocate for science and biomedical research.
42:15 Listener Questions & Discussion: Topics include appropriate controls for vaccine trials (reaffirming saline-only is a step back), verifying MMR immunity through serology, managing dental health without water fluoridation due to recent state bans, and the ProMED-mail service shifting to a subscription model.